MX385276B - Tratamiento para la enfermedad de parkinson - Google Patents
Tratamiento para la enfermedad de parkinsonInfo
- Publication number
- MX385276B MX385276B MX2018014944A MX2018014944A MX385276B MX 385276 B MX385276 B MX 385276B MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 385276 B MX385276 B MX 385276B
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- haloalkyl
- hydrogen
- disease
- parkinson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion se refiere a un metodo de tratamiento o prevencion de la enfermedad de Parkinson en un sujeto que comprende administrar un compuesto de Formula I en donde, R1 es -NHC(O) C3-6 cicloalquilo y R2 es hidrogeno; o R1 y R2 junto con los atomos de carbono a los que estan unidos forman un anillo aromatico de seis miembros, en donde el anillo esta sustituido con uno o mas grupos seleccionados a partir de hidrogeno y halogeno, alquilo C1-6; R3 y R4 se seleccionan independientemente de entre el grupo que comprende hidrogeno, halogeno, C1-3 alquilo, OC1-3 alquilo, NO2, SC1-3 alquilo, C1-3 haloalquilo, OC1-3 haloalquilo y SC1-3 haloalquilo; o una sal farmaceuticamente aceptable de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621019087 | 2016-06-02 | ||
| IN201621019185 | 2016-06-02 | ||
| PCT/IN2017/050224 WO2017208267A1 (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014944A MX2018014944A (es) | 2019-03-07 |
| MX385276B true MX385276B (es) | 2025-03-18 |
Family
ID=59388123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014944A MX385276B (es) | 2016-06-02 | 2017-06-02 | Tratamiento para la enfermedad de parkinson |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10849887B2 (es) |
| EP (2) | EP3463351B1 (es) |
| JP (1) | JP6974357B2 (es) |
| KR (1) | KR102508288B1 (es) |
| CN (1) | CN109475539B (es) |
| AU (1) | AU2017273415B2 (es) |
| CA (1) | CA3024976A1 (es) |
| CL (1) | CL2018003431A1 (es) |
| CY (1) | CY1125285T1 (es) |
| DK (1) | DK3463351T3 (es) |
| ES (1) | ES2914782T3 (es) |
| HR (1) | HRP20220683T1 (es) |
| HU (1) | HUE059387T2 (es) |
| IL (1) | IL263188B (es) |
| LT (1) | LT3463351T (es) |
| MX (1) | MX385276B (es) |
| MY (1) | MY193754A (es) |
| NZ (1) | NZ748592A (es) |
| PH (1) | PH12018502457B1 (es) |
| PL (1) | PL3463351T3 (es) |
| PT (1) | PT3463351T (es) |
| RS (1) | RS63243B1 (es) |
| SG (1) | SG11201810294QA (es) |
| SI (1) | SI3463351T1 (es) |
| SM (1) | SMT202200228T1 (es) |
| UA (1) | UA123018C2 (es) |
| WO (1) | WO2017208267A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2844256B1 (en) | 2012-05-02 | 2023-02-22 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
| CN109475539B (zh) * | 2016-06-02 | 2021-12-28 | 太阳医药高级研究有限公司 | 帕金森氏病的治疗 |
| CN110606840A (zh) | 2018-06-15 | 2019-12-24 | 日产化学株式会社 | 5-炔基吡啶化合物的制造方法 |
| AU2019385480B2 (en) | 2018-11-20 | 2025-04-24 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
| KR20220024463A (ko) * | 2019-06-11 | 2022-03-03 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 시뉴클레인병증에 대한 치료 |
| WO2021030783A1 (en) * | 2019-08-15 | 2021-02-18 | Duke University | Compositions and methods for the treatment cancer and cns disorders |
| EP4188351A1 (en) | 2020-07-31 | 2023-06-07 | Sun Pharma Advanced Research Company Ltd | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease |
| US20250275953A1 (en) | 2022-05-02 | 2025-09-04 | Sun Pharma Advanced Research Company Ltd. | Vodobatinib for reducing progression of parkinson's disease |
| WO2025058473A1 (ko) | 2023-09-14 | 2025-03-20 | 주식회사 엑소스템텍 | 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2608829T3 (es) * | 2011-01-21 | 2017-04-17 | Sun Pharma Advanced Research Company Limited | Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida |
| EP2844256B1 (en) | 2012-05-02 | 2023-02-22 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
| CN107709300A (zh) * | 2015-05-18 | 2018-02-16 | 太阳医药高级研究有限公司 | 新型酰胺基杂芳基芳酰基酰肼乙炔 |
| CN109475539B (zh) * | 2016-06-02 | 2021-12-28 | 太阳医药高级研究有限公司 | 帕金森氏病的治疗 |
-
2017
- 2017-06-02 CN CN201780044265.3A patent/CN109475539B/zh active Active
- 2017-06-02 KR KR1020187034626A patent/KR102508288B1/ko active Active
- 2017-06-02 MY MYPI2018002187A patent/MY193754A/en unknown
- 2017-06-02 CA CA3024976A patent/CA3024976A1/en active Pending
- 2017-06-02 PL PL17743097T patent/PL3463351T3/pl unknown
- 2017-06-02 AU AU2017273415A patent/AU2017273415B2/en not_active Ceased
- 2017-06-02 EP EP17743097.2A patent/EP3463351B1/en active Active
- 2017-06-02 HR HRP20220683TT patent/HRP20220683T1/hr unknown
- 2017-06-02 DK DK17743097.2T patent/DK3463351T3/da active
- 2017-06-02 UA UAA201812407A patent/UA123018C2/uk unknown
- 2017-06-02 MX MX2018014944A patent/MX385276B/es unknown
- 2017-06-02 SG SG11201810294QA patent/SG11201810294QA/en unknown
- 2017-06-02 JP JP2018563062A patent/JP6974357B2/ja active Active
- 2017-06-02 LT LTEPPCT/IN2017/050224T patent/LT3463351T/lt unknown
- 2017-06-02 HU HUE17743097A patent/HUE059387T2/hu unknown
- 2017-06-02 US US16/304,914 patent/US10849887B2/en active Active
- 2017-06-02 SI SI201731157T patent/SI3463351T1/sl unknown
- 2017-06-02 NZ NZ748592A patent/NZ748592A/en unknown
- 2017-06-02 RS RS20220497A patent/RS63243B1/sr unknown
- 2017-06-02 WO PCT/IN2017/050224 patent/WO2017208267A1/en not_active Ceased
- 2017-06-02 EP EP22169420.1A patent/EP4085912A1/en active Pending
- 2017-06-02 PT PT177430972T patent/PT3463351T/pt unknown
- 2017-06-02 ES ES17743097T patent/ES2914782T3/es active Active
- 2017-06-02 SM SM20220228T patent/SMT202200228T1/it unknown
-
2018
- 2018-11-21 IL IL263188A patent/IL263188B/en unknown
- 2018-11-22 PH PH12018502457A patent/PH12018502457B1/en unknown
- 2018-11-30 CL CL2018003431A patent/CL2018003431A1/es unknown
-
2020
- 2020-10-01 US US17/061,139 patent/US11583522B2/en active Active
-
2022
- 2022-05-18 US US17/747,472 patent/US11813252B2/en active Active
- 2022-05-27 CY CY20221100369T patent/CY1125285T1/el unknown
-
2023
- 2023-10-11 US US18/378,901 patent/US20240066014A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385276B (es) | Tratamiento para la enfermedad de parkinson | |
| CR20180022A (es) | Derivados etinilo. | |
| MX379474B (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales | |
| ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR095823A1 (es) | Compuesto de ciclopropanamina y uso del mismo | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| PE20140934A1 (es) | Derivados de pirazol | |
| UY36257A (es) | “compuestos de imidazopiridazina”. | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| AR099047A1 (es) | Derivados etinilo | |
| AR081821A1 (es) | Antranilamidas sustituidas con triazol como plaguicidas | |
| UY31824A (es) | Nuevos compuestos | |
| CU20100252A7 (es) | Derivados de dibenzotiazepina | |
| UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| MX345264B (es) | Derivado de azol. | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria |